Jump to content

All Activity

This stream auto-updates

  1. Earlier
  2. https://www.cureus.com/articles/167601-protein-s-deficiency-and-covid-19-a-brutal-combination-leading-to-acute-submassive-bilateral-pulmonary-embolism#!/ Abstract: Protein S deficiency is a form of inherited thrombophilia that occurs due to low levels of or improper function of protein S. The role of protein S is to inactivate procoagulant factors, and a deficiency results in an increased risk of thrombotic events. The coronavirus disease 2019 (COVID-19) infection has also been studied to increase the risk of venous thromboembolism (VTE) due to an interplay of several mechanisms. However, the risk of VTE in patients affected by both of these disease processes simultaneously has not been thoroughly studied, and so recommendations regarding routine screening and prophylaxis of VTE have also not been established. We discuss the case of a 46-year-old woman with a past history of protein S deficiency and a recent COVID-19 infection who presented with complaints of shortness of breath. Upon examination, she was found to be hypoxic and tachycardic. A computed tomography angiography of the chest was done and revealed acute submassive bilateral pulmonary embolism with right heart strain and pulmonary infarcts. She was initially treated with intravenous heparin and later transitioned to oral anticoagulation for a minimum of six months.
  3. 'A miracle': Palm Coast woman gives birth roadside on her way to Flagler Hospital Roadside birth underscores the lack of birthing facilities in Palm Coast. Brenno Carillo, The Daytona Beach News-Journal Given her high-risk pregnancy, Isis Davis couldn’t take any chances delivering her first child, so she patiently awaited July 13, the day she was scheduled to be induced. But the morning of June 25, she started feeling cramps. Davis called her doula, Tabatha Seppala, and told her about the pain. When Seppala arrived at her house soon after, she knew something was wrong. A few hours later, Seppala, Davis and Davis' husband, Anthony, found themselves at the intersection of U.S. 1 and State Road 206 with baby Akovi Davis in their hands, in a happy ending to a story that could have ended tragically, Seppala said. In an interview with The News-Journal, Seppala recounted what happened during the unforgettable day. Full article: https://eu.news-journalonline.com/story/news/local/flagler/2023/07/06/palm-coast-woman-gives-birth-roadside-on-her-way-to-flagler-hospital/70361088007/
  4. Proteomic-based identification of APCS as candidate protein for diagnosis of patients exhibiting anti-tubercular drug induced liver injury https://www.nature.com/articles/s41598-023-35930-x Extract: Furthermore, TB with hepatotoxicity group (Group 4) in comparison to TB without hepatotoxicity (Group 3) showed 24 significant differentially expressed proteins (Table 7, Fig. 5A a–c). Vitamin K-dependent protein S (PROS), ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase (Fragment) (BST1) and Apolipoprotein B-100 (APOB) were found to be upregulated whereas downregulated proteins include Phosphatidylcholine-sterol acyltransferase (LCAT), Adiponectin (ADIPOQ), Serum amyloid P-component (APCS), Proteoglycan 4 (PRG4) and Transthyretin (TTR). Some of the observed proteins were similar to the identified proteins in TB with hepatotoxicity (Group 4) compared to newly diagnosed TB group (Group 2) (Fig. 4a) or with the healthy group (Group 1) (data shown in supplementary Fig. 1). Noteworthy, some protein signatures like PROS1, KNG1, CFH, LCAT, APCS and ADIPOQ showed the potential to distinguish the hepatotoxicity group from other defined study groups. However, only APCS protein showed significant downregulation in Group 4 as compared to Groups 1,2,3 suggesting its potential role in anti-tubercular drug induced hepatotoxicity (Fig. 5B).
  5. 23rd May 2023. The US Food and Drug Administration (FDA) has granted Vega Therapeutics with orphan drug designation for VGA039 for the treatment of the rare bleeding disorder, von Willebrand disease (VWD). https://www.businesswire.com/news/home/20230523005266/en/Vega-Therapeutics-Receives-FDA-Orphan-Drug-Designation-for-VGA039-for-the-Treatment-of-von-Willebrand-Disease
  6. https://www.businesswire.com/news/home/20230405005728/en/Vega-Therapeutics-Initiates-Clinical-Trial-Program-for-VGA039-a-First‑in‑Class-Antibody-Therapy-for-von-Willebrand-Disease 6th April 2023. Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced that its clinical trial program for VGA039 has been initiated.
  1. Load more activity
  • Create New...